Metformin Hydrochloride is named as an intervention in 4 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is PMV Pharmaceuticals, Inc (1). The most-studied condition is TP53 Y220C Mutation.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Pilot Study on Evaluating the Geroprotective Effect of Metformin
NCT06459310 · ClinicalTrials.gov ↗ · Metformin, Aging
|
Phase 2 | Recruiting | Xuanwu Hospital, Beijing | China |
|
A Study of Metformin to Improve Cardiac Function After LVAD Implantation
NCT07666698 · ClinicalTrials.gov ↗ · Heart Failure, Left Ventricular Assist Device
|
Phase 1/2 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | China |
|
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
NCT07372625 · ClinicalTrials.gov ↗ · TP53 Y220C Mutation, Advanced Solid Tumors
|
Phase 1 | Recruiting | PMV Pharmaceuticals, Inc | USA |
|
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
NCT07785934 · ClinicalTrials.gov ↗ · Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
|
Phase 1 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| PMV Pharmaceuticals, Inc | 1 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| Xuanwu Hospital, Beijing | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China and USA registers name Metformin Hydrochloride as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 3 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
PMV Pharmaceuticals, Inc (1), The United Bio-Technology (Hengqin) Co., Ltd (1), The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) and Xuanwu Hospital, Beijing (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Metformin Hydrochloride works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Metformin Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Metformin Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.